Drug-tolerant persister cells in cancer: the cutting edges and future directions - Institut de cancérologie de l'Ouest Access content directly
Journal Articles Nature Reviews Clinical Oncology Year : 2023

Drug-tolerant persister cells in cancer: the cutting edges and future directions

Abstract

Drug-tolerant persister (DTP) cell populations were originally discovered in antibiotic-resistant bacterial biofilms. Similar populations with comparable features have since been identified among cancer cells and have been linked with treatment resistance that lacks an underlying genomic alteration. Research over the past decade has improved our understanding of the biological roles of DTP cells in cancer, although clinical knowledge of the role of these cells in treatment resistance remains limited. Nonetheless, targeting this population is anticipated to provide new treatment opportunities. In this Perspective, we aim to provide a clear definition of the DTP phenotype, discuss the underlying characteristics of these cells, their biomarkers and vulnerabilities, and encourage further research on DTP cells that might improve our understanding and enable the development of more effective anticancer therapies.
Fichier principal
Vignette du fichier
Shen_NRCO-22-258_V3_rec_1690559378_1.pdf (641.97 Ko) Télécharger le fichier
60308_3_figure_562483_rzdz6q_convrt.pdf (1.21 Mo) Télécharger le fichier
60308_3_figure_562484_rzdz6q_convrt.pdf (3.31 Mo) Télécharger le fichier
60308_3_figure_562485_rzdz6q_convrt.pdf (121.14 Ko) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

inserm-04501799 , version 1 (12-03-2024)

Identifiers

Cite

Yi Pu, Lu Li, Haoning Peng, Lunxu Liu, Dominique Heymann, et al.. Drug-tolerant persister cells in cancer: the cutting edges and future directions. Nature Reviews Clinical Oncology, 2023, 20 (11), pp.799-813. ⟨10.1038/s41571-023-00815-5⟩. ⟨inserm-04501799⟩
0 View
5 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More